|
This complaint is from a literature source-the following literature cite has been reviewed- de potter t, sarkozy a, duytschaever m, bulava a.Safety and efficacy of catheter ablation on patients with persistent atrial fibrillation by targeting repetitive activation patterns and focal impulses.Pacing clin electrophysiol.2023 jul;46(7):729-737.Doi: 10.1111/pace.14708.Epub 2023 may 20.Pmid: 37208935.No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because no lot number was provided by the customer.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster, inc., or its employees that the report constitutes an admission that the product, biosense webster, inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's ref #: (b)(4).
|
|
This complaint is from a literature source-the following literature cite has been reviewed- de potter t, sarkozy a, duytschaever m, bulava a.Safety and efficacy of catheter ablation on patients with persistent atrial fibrillation by targeting repetitive activation patterns and focal impulses.Pacing clin electrophysiol.2023 jul;46(7):729-737.Doi: 10.1111/pace.14708.Epub 2023 may 20.Pmid: 37208935.Objective/methods/study data:the study is intended to evaluate the acute and long-term effectiveness and peri-procedural safety in ablation of persistent atrial fibrillation (psaf) using the cartofinder algorithm guided ablation (cfga) targeting on repetitive activation patterns (raps) and focal impulses (fis) identified in dynamic maps.Sixty-four psaf patients (age, 60.7 ± 9.1 years; male, 76.6%; median psaf duration, 6.0 months) underwent cfga on raps/fis.Six patients (9.4%) reported primary adverse event (pae) including groin hematoma (2), complete heart block (1), tamponade (1), pericarditis (1), and pseudoaneurysm (1).Repeated mapping and ablation on raps/fis resulted in the cycle length (cl) increase from 191.0 ± 167.6 ms at baseline to 365.7 ± 296.7 ms in the la and from 167.8 ± 41.6 ms to 379.4 ± 293.5 ms in the ra and 30.2% (19/63) af termination to sr or organized at.The 12-month arrhythmia-free and symptomatic af-free rates were 60.9% and 75.0%, respectively.Patients with acute af termination showed a higher 12-month arrhythmia-free rate (76.9%) than those without (50.0%, p =.04).Lot, model and catalog number are not available, but the suspected biosense device possibly associated with reported adverse events: (thermocool smarttouch tm catheter [st], biosense webster, irvine, ca.Other biosense webster devices that were also used in this study: cartofindertm, biosense webster,irvine, ca) , non-biosense webster devices that were also used in this study: multielectrode basket-shaped mapping catheter (constellationtm, boston scientific).Adverse event(s) and provided interventions qty 1 -cardiac tamponade, epicardial drainage leading to recovery.Qty 1 - complete atrioventricular conduction block requiring implantation of pacemaker.Qty 1- pericarditist, fully recovered in 5 days.
|